Solubilization and characterization of binding sites for [3H]NE-100, a novel and potent sigma1 ligand, from guinea pig brain

Life Sciences

Volumn 59, Issue 16, 1996, Pages 1331-1340

  Chaki, Shigeyuki ^a   Okuyama, Shigeru ^a   Ogawa, Shin Ichi ^a   Tanaka, Makoto ^b   Muramatsu, Makoto ^c   Nakazato, Atsuro ^a   Tomisawa, Kazuyuki ^a  

^a Medicinal Research Laboratories   (Japan)

^b Pharmaceutical Res Labs   (Japan)

^c TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

(+) pentazocine thyrotropin releasing hormone; NE 100; sigma binding protein; solubilization

Indexed keywords

1 CYCLOPROPYLMETHYL 4 [2 (4 FLUOROPHENYL) 2 OXOETHYL]PIPERIDINE; 1,3 BIS(2 METHYLPHENYL)GUANIDINE; 2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; 3 [(3 CHOLAMIDOPROPYL)DIMETHYLAMMONIO] 1 PROPANESULFONIC ACID; AMPHOLYTE; BENZOMORPHAN DERIVATIVE; BINDING PROTEIN; DETERGENT; DEXTROMETHORPHAN; HALOPERIDOL; N ALLYLNORMETAZOCINE; PENTAZOCINE; PHENCYCLIDINE; PHENYTOIN; PROPRANOLOL; RADIOLIGAND; SIGMA 1 OPIATE RECEPTOR; SIGMA OPIATE RECEPTOR ANTAGONIST; SIGMA OPIATE RECEPTOR LIGAND; SIGMA OPIATE RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; BINDING SITE; BRAIN MEMBRANE; CONTROLLED STUDY; GEL FILTRATION CHROMATOGRAPHY; GUINEA PIG; MALE; MOLECULAR WEIGHT; NONHUMAN; RECEPTOR SOLUBILIZATION; STEREOSPECIFICITY;

ANIMALIA; CAVIA PORCELLUS; SUS SCROFA;

EID: 0030582455     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/0024-3205(96)00458-4     Document Type: Article

References (19)

1. 1. S. OKUYAMA, Y. IMAGAWA, S. OGAWA, H. ARAKI, M. TANAKA, M. MURAMATSU, A. NAKAZATO, K. YAMAGUCHI, M. YOSHIDA and S. OTOMO, Life Sci., 53 PL285-290 (1993).
2. 2. S. OKUYAMA, Y. IMAGAWA, T. SAKAGAWA, A. NAKAZATO, K. YAMAGUCHI, M. KATOH, S. YAMADA, H. ARAKI and S. OTOMO, Life Sci., 55 PL133-138 (1994).
3. 3. M. TANAKA, T. SHIRASAKI, S. KAKU, M. MURAMATSU and S. OTOMO, Naunyn-Schmiedeberg's Arch. Pharmacol. 351 244-251 (1995).
4. 4. R. QUIRION, W. BOWEN, Y. ITZHAK, J.L. JUNIEN, J.M. MUSACCHIO, R.B. ROTHMAN, T.-P. SU , S.W. TAM and D.P. TAYLOR, Trends in Pharmacol. Sci., 13 85-86 (1992).
5. 5. S. CHAKI, M. TANAKA, M. MURAMATSU and S. OTOMO, Eur. J. Pharmacol. 251 R1-R2 (1994).
6. 6. J.M. WALKER, R.R. MATSUMOTO, W.D. BOWEN, D.L. GANS, K.D. JONES and F.O. WALKER, Neurology, 38 961-965 (1988).
7. 7. J.M. WALKER, W.D. BOWEN, S.L. PATRICK, W.E. WILLIAMS, S.W. MASCARELLA, X. BAI, and F.I. CARROLL, Eur. J. Pharmacol., 231 61-68 (1993).
8. 8. M.M. BRADFORD, Anal. Biochem. 72 248-254 (1976).
9. 9. E,M, KARBON, K. NAPER and M.J. PONTECORVO, Eur. J. Pharmacol. 193 21-27 (1991).
10. 10. J.M. MUSACCHIO, M. KLEIN and L.J. SANTIAGO, Neuropharmacol. 26 997-1001 (1987).
11. 11. W.D. BOWEN, B.R. DE COSTA, S.B. HELLEWELL, J.M. WAKER and K.C. RICE, Mol. Pharmacol. 3 117-126 (1993)
12. 12. M.P. KAVANAUGH, B.C. TESTER, M.W. SCHERZ, J.F.W. KEANA and E. WEBER, Proc. Natl. Acad. Sci. USA, 85 2844-2848 (1988).
13. 13. D.J. MCCANN and T.-P. SU, J. Pharmacol. Exp. Ther., 257 547-554 (1991).
14. 14. S.B. HELLEWELL, A. BRUCE, G. FEINSTEIN, J. ORRINGER, W. WILLIAMS and M.D. BOWEN, Eur. J. Pharmacol. 268 9-18 (1994).
15. 15. M.P. KAVANAUGH, J. PARKER, D.H. BOBKER, J.F.W. KEANA and E. WEBER, J. Neurochem., 53 1575-1580 (1989).
16. 16. S. OKUYAMA, S. CHAKI, T. YAE, A. NAKAZATO and M. MURAMATSU, Life Sci., 57 PL333-337 (1995).
17. 17. H.Y AMAMOTO, T. YAMAMOTO, N. SAGI, S. OKUYAMA, N. KAWAI, A. BABA and T. MOROJI, Life Sci., 56 39-43 (1994).
18. 18. H. YAMAMOTO, T. YAMAMOTO, N. SAGI , V. KLENEROVA, K. GOJI, N. KAWAI, A. BABA, E. TAKAMORI and T. MOROJI, J. Neurosci., 15 731-736 (1995).
19. 19. S. OKUYAMA, Y. IMAGAWA and K. TOMISAWA, Neuropharmacol. in press (1996).